Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 8c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.76), $0.08 better than the analyst estimate of ($0.84).

“This is a very exciting time for our company,” said Dr. Sharon Mates, Chairman and CEO of ITCI. “We are pleased with the progress we have made in numerous areas including the completion of our new drug application submission to the FDA for lumateperone for the treatment of schizophrenia, the completion of patient enrollment in our lumateperone bipolar depression trial (Study 401 – U.S. monotherapy) and the favorable results in our Phase 1/2 trial of our phosphodiesterase 1 inhibitor, ITI-214, in patients with Parkinson’s disease. In addition, we have strengthened our management team, including the appointment of a Chief Commercial Officer as we prepare for the commercialization of lumateperone if it is approved for sale in the U.S.”

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ledyard Financial Group names Charles Petersen as board chair
• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea